We invest in
companies
to catalyze their growth
adMare has helped build 36 companies, of which 25 are still active. These companies have attracted $2.4 billion of risk capital, have a combined value of $5.7 billion, and have created around 1,000 jobs in Canada.
Discover our companies below.
The companies we've helped build have grown under adMare's guidance and support, encompassing both financial backing and business development.
Thryv Therapeutics Inc.
Description
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.), is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. This strategic evolution has secured an additional US$15M financing fuelling Thryv to complete a proof-of-concept study for LQTS, and submit an IND for the treatment of resistant cancer.
More information
Back to list
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
